Post Profile






Cystic Fibrosis Drug Shows Promise in Children as Young as 1 Year of Age

Ann & Robert H. Lurie Children's Hospital of Chicago is one of the study sites in the open label Phase 3 study that showed safety and effectiveness of the cystic fibrosis drug Kalydeco (ivacaftor) in children ages 1 to 2 years. Based on these results, Vertex Pharmaceuticals Inc., (Nasdaq: VRTX) plans to submit applications for the drug in this age group to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
read more

share

Related Posts


Study Evaluates Use of Inhaled Saline for Young Children with Cystic Fibrosis

Health : Newswise Medical News

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic ...

Ivacaftor Improves Lung Function And Symptoms In Cystic Fibrosis Patients With Specific Genetic Mutation

Health : Medical News Today

Ivacaftor, a novel oral agent that potentiates a membrane channel blocked in patients aged six years and older with cystic fibrosis caused by the G551D mutation, significantly improves lung function and reduces pulmonary exacerbatio...

The Lancet Respiratory Medicine: Benefits of cystic fibrosis drug ivacaftor reported in pre-school children for the first time

Academics / General Science : Science Codex

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The Lancet Respiratory Medicine journal...

New Medication Effectively Treats Underlying Cause Of Cystic Fibrosis

Health : Medical News Today

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cyst...

New Drug Combination Therapy for Cystic Fibrosis Shows Promise

Health : Newswise Medical News

Studies show a two-drug combination therapy for cystic fibrosis, using tezacaftor and ivacaftor, is effective. UAB researchers say triple combination therapy is close behind.

Comments


Copyright © 2016 Regator, LLC